Saltar al contenido
PivotalWire
Lunes 12 oct 2026SEC · NASDAQ biomédico

Portada›Viernes 28 de noviembre de 2025

Biomédicas del NASDAQ ante la SEC, viernes 28 de noviembre de 2025

Los 18 documentos que 15 empresas del sector presentaron ante la SEC ese día, agrupados por tipo y con el enlace al original en EDGAR.

·

El día, bloque a bloque

Va en color lo que cambia el capital o avisa de un riesgo: las emisiones con precio (424B1, 424B2, 424B4 y 424B5), los 8-K con item 1.02, 1.03, 2.04, 3.01, 3.02 y 4.02, y cualquier documento en el que haya aparecido una frase vigilada, que va citada debajo. Lo demás va en tinta normal. Una cita marcada «por primera vez» es una frase que no estaba en el informe previo del mismo tipo de esa empresa. La etiqueta del formulario lleva a su explicación.

Emisiones y dilución

  1. ACTUACTUATE THERAPEUTICS, INC.424B5Nueva emisión de acciones con precioEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…will not satisfy our operational and capital requirements beyond the second quarter of fiscal year 2026 without raising additional capital. Based on the above matters, we have concluded that there is substantial doubt regarding the Company’s ability to continue as a going concern. S-4 We will consider alternatives to our current business plan that may enable to us to achieve revenue producing operations and meaningful commercial success with a smaller amount of capital. However…
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸…9-8-25 Filed Pursuant to Rule 424(b)(5) Registration No. 333-289988 PROSPECTUS SUPPLEMENT (to the Prospectus dated September 8, 2025) Up to $100,000,000 of Common Stock Actuate Therapeutics, Inc. has entered into an At the Market Issuance Sales Agreement (the “Sales Agreement”), with B. Riley Securities, Inc. and Craig-Hallum Capital Group LLC (each a “Sales Agent” and collectively the “Sales Agents”) relating to the sale of shares of our common stock…
  2. DWTXDogwood Therapeutics, Inc.424B5Nueva emisión de acciones con precioEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing. The report of Forvis Mazars LLP contains an explanatory paragraph regarding substantial doubt about the Company’s ability to continue as a going concern. WHERE YOU CAN FIND ADDITIONAL INFORMATION; INCORPORATION BY REFERENCE Available Information We have filed with the SEC a registration statement on Form S-3 under the Securities Act, and the rules and…
  3. GANXGain Therapeutics, Inc.424B5Nueva emisión de acciones con precioEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…to be sold in this offering. Investors may experience a decline in the value of the shares they purchase in this offering as a result of sales made at prices lower than the prices they paid. There is substantial doubt about our ability to continue as a going concern. We have a history of operating losses and expect to incur losses for the foreseeable future. We may never generate revenues or, if we are able to generate revenues, achieve profitability. We are focused…
  4. SPRCSciSparc Ltd.424B5Nueva emisión de acciones con precioEDGAR

Participaciones y control

  1. VRCAVerrica Pharmaceuticals Inc.SC 13D/ACambio en participación significativaEDGAR
    En el documentoContrasplit de accionestexto original ▸…as filed with the Securities and Exchange Commission (the "SEC") on July 15, 2022 (the "Initial Schedule 13D"), as amended on November 26, 2024 ("Amendment No. 1"). Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein has been adjusted to reflect the reverse stock split. All capitalized terms not otherwise defined herein shall have the meanings…
  2. LABSTANDARD BIOTOOLS INC.SC 13D/ACambio en participación significativaEDGAR
  3. LNAILunai Bioworks Inc.SC 13D/ACambio en participación significativaEDGAR
  4. NEUPNeuphoria Therapeutics Inc.SC 13D/ACambio en participación significativaEDGAR

Informes y hechos relevantes

  1. MBRXMoleculin Biotech, Inc.8-KCambio de estatutosEDGAR
    En el documentoContrasplit de accionestexto original ▸…s board of directors in its sole discretion prior to the one-year anniversary of the annual meeting. Pursuant to such authority granted by the Company’s stockholders, the Company’s board of directors approved a one-for-twenty-five (1:25) reverse stock split (the “Reverse Stock Split”) of the Company’s common stock and the filing of the Amendment to effectuate the Reverse Stock Split. The Amendment was filed with the Secretary of State of the State of Delaware…
  2. ACTUACTUATE THERAPEUTICS, INC.8-KNuevo acuerdo materialEDGAR
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸…financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ Item 1.01 Entry into a Material Definitive Agreement. On November 28, 2025, Actuate Therapeutics, Inc. (the “Company”) entered into an At the Market Issuance Sales Agreement (the “Agreement”) with B. Riley Securities, Inc. and Craig-Hallum Capital Group LLC (each a “Sales Agent” and collectively the “Sales Agents”) under which the Company may offer and sell, from time to…
  3. DWTXDogwood Therapeutics, Inc.8-KNuevo acuerdo materialEDGAR
  4. GANXGain Therapeutics, Inc.8-KOtros hechos relevantesEDGAR
  5. IMCRImmunocore Holdings plc8-KCambio en el consejo o la direcciónEDGAR
  6. INMBInmune Bio, Inc.8-KCambio en el consejo o la direcciónEDGAR
  7. LEXXLexaria Bioscience Corp.10-KInforme anualEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…obtain additional equity, effect a collaborative or strategic partnership, reduce or contain expenditures, and, ultimately, to generate revenue. Based on these factors, management determined that there is substantial doubt as to our ability to continue as a going concern. If we are unable to continue as a going concern, we may have to liquidate our assets and may receive less than the value at which those assets are carried on our audited financial statements, and it…
  8. SHPHShuttle Pharmaceuticals Holdings, Inc.8-KCambio en el consejo o la direcciónEDGAR
    En el documentoCambio en la dirección de la empresatexto original ▸…Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On November 21, 2025, Timothy Lorber resigned as Chief Financial Officer of Shuttle Pharmaceuticals Holdings, Inc. (the “Company”), effective immediately. In connection with Mr. Lorber’s resignation, Mr. Lorber and the Company entered into a Separation Agreement and Mutual…
  9. TRAWTraws Pharma, Inc.8-KCambio en el consejo o la direcciónEDGAR
  10. VNDAVanda Pharmaceuticals Inc.8-KOtros hechos relevantesEDGAR
    En el documentoFecha de decisión de la FDA (PDUFA)texto original ▸…term studies •Separately, FDA recently issued labeling comments, and labeling discussions have formally begun for the New Drug Application of tradipitant for the prevention of vomiting induced by motion (PDUFA target action date remains December 30, 2025) WASHINGTON, Nov. 28, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced the following updates regarding tradipitant for motion sickness: Partial Clinical Hold Re…

·

Esto mismo, cada mañana y solo de tus empresas. Sigue a las que te interesen y recibe en tu correo lo que presenten ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.

Esto no son recomendaciones de inversión. Son hechos públicos verificables en su fuente. Lee siempre el documento original antes de decidir nada. Aviso legal.